Misplaced Pages

Taniborbactam: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactivelyContent deleted Content addedVisualWikitext
Revision as of 21:10, 24 December 2024 editInnerstream (talk | contribs)Autopatrolled, Extended confirmed users3,981 edits new pageTag: nowiki added  Latest revision as of 10:18, 26 December 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,602 edits added Category:Heterocyclic compounds with 2 rings using HotCat 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = | drug_name =
Line 50: Line 51:
| synonyms = VNRX-5133, VNRX5133 | synonyms = VNRX-5133, VNRX5133
| CAS_number = 1613267-49-4 | CAS_number = 1613267-49-4
| CAS_supplemental =
| PubChem = 76902493 | PubChem = 76902493
| PubChemSubstance =
⚫ | UNII = 8IGQ156Z07
| IUPHAR_ligand =
| DrugBank = | DrugBank =
| ChemSpiderID = 115037173
⚫ | UNII = 8IGQ156Z07
| KEGG = D11718
| ChEBI =
| ChEMBL = 4463697
| NIAID_ChemDB =
| PDB_ligand =
<!-- Chemical and physical data --> <!-- Chemical and physical data -->
| IUPAC_name = (3''R'')-3-<nowiki>acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid | IUPAC_name = (3''R'')-3-<nowiki>acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
| smiles = B1((CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O | smiles = B1((CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O
| C = 19 | H = 28 | B = 1 | N = 3 | O = 5 | C = 19 | H = 28 | B = 1 | N = 3 | O = 5
| StdInChI = InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
| StdInChI_comment =
| StdInChIKey = PFZUWUXKQPRWAL-PXCJXSSVSA-N
}} }}


'''Taniborbactam''' (development code '''VNRX-5133''') is a pharmaceutical drug that acts as a ].<ref>{{cite journal | doi = 10.1021/acs.jmedchem.9b01518 }}</ref> It inhibits the function of bacterial ]s which impart resistance to ]s. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the ] group which are the most frequently identified sources of acquired antibiotic resistance worldwide.<ref>{{cite journal | doi = 10.1016/S1473-3099(23)00069-5 }}</ref> '''Taniborbactam''' (development code '''VNRX-5133''') is a pharmaceutical drug that acts as a ].<ref>{{cite journal | vauthors = Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, Daigle DM, Cusick SM, Pozzi C, De Luca F, Benvenuti M, Mangani S, Docquier JD, Weiss WJ, Pevear DC, Xerri L, Burns CJ | title = Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections | journal = Journal of Medicinal Chemistry | volume = 63 | issue = 6 | pages = 2789–2801 | date = March 2020 | pmid = 31765155 | pmc = 7104248 | doi = 10.1021/acs.jmedchem.9b01518 }}</ref> It inhibits the function of bacterial ]s which impart resistance to ]s. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the ] group which are the most frequently identified sources of acquired antibiotic resistance worldwide.<ref>{{cite journal | vauthors = Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L | title = NDM-9 resistance to taniborbactam | journal = The Lancet. Infectious Diseases | volume = 23 | issue = 4 | pages = 401–402 | date = April 2023 | pmid = 36796395 | doi = 10.1016/S1473-3099(23)00069-5 }}</ref>


Taniborbactam, in combination with ], is in clinical trials for the treatment of bacterial infections, including ] and ].<ref>{{cite journal | doi = 10.1056/NEJMoa2304748 }}</ref><ref>{{cite web | url = https://adisinsight.springer.com/drugs/800049949 | title = Cefepime/taniborbactam - VenatoRx Pharmaceuticals | publisher = AdisInsight }}</ref> Taniborbactam, in combination with ], is in clinical trials for the treatment of bacterial infections, including ] and ].<ref>{{cite journal | vauthors = Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T | title = Cefepime-Taniborbactam in Complicated Urinary Tract Infection | journal = The New England Journal of Medicine | volume = 390 | issue = 7 | pages = 611–622 | date = February 2024 | pmid = 38354140 | doi = 10.1056/NEJMoa2304748 | author9 = CERTAIN-1 Study Team }}</ref><ref>{{cite web | url = https://adisinsight.springer.com/drugs/800049949 | title = Cefepime/taniborbactam - VenatoRx Pharmaceuticals | work = AdisInsight | publisher = Springer Nature Switzerland AG }}</ref>


==References== ==References==
Line 69: Line 82:


] ]
]
] ]
] ]
]
]
]

Latest revision as of 10:18, 26 December 2024

Pharmaceutical compound
Taniborbactam
Clinical data
Other namesVNRX-5133, VNRX5133
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • (3R)-3-acetyl]amino]-2-hydroxy-3,4-dihydro-1,2-benzoxaborinine-8-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC19H28BN3O5
Molar mass389.26 g·mol
3D model (JSmol)
SMILES
  • B1((CC2=C(O1)C(=CC=C2)C(=O)O)NC(=O)CC3CCC(CC3)NCCN)O
InChI
  • InChI=InChI=1S/C19H28BN3O5/c21-8-9-22-14-6-4-12(5-7-14)10-17(24)23-16-11-13-2-1-3-15(19(25)26)18(13)28-20(16)27/h1-3,12,14,16,22,27H,4-11,21H2,(H,23,24)(H,25,26)/t12?,14?,16-/m0/s1
  • Key:PFZUWUXKQPRWAL-PXCJXSSVSA-N

Taniborbactam (development code VNRX-5133) is a pharmaceutical drug that acts as a β-lactamase inhibitor. It inhibits the function of bacterial β-lactamases which impart resistance to β-lactam antibiotics. However, unlike other β-lactamase inhibitors that are used as pharmaceuticals, taniborbactam is effective against enzymes of the New Delhi metallo-beta-lactamase 1 group which are the most frequently identified sources of acquired antibiotic resistance worldwide.

Taniborbactam, in combination with cefepime, is in clinical trials for the treatment of bacterial infections, including urinary tract infection and pyelonephritis.

References

  1. Liu B, Trout RE, Chu GH, McGarry D, Jackson RW, Hamrick JC, et al. (March 2020). "Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections". Journal of Medicinal Chemistry. 63 (6): 2789–2801. doi:10.1021/acs.jmedchem.9b01518. PMC 7104248. PMID 31765155.
  2. Le Terrier C, Gruenig V, Fournier C, Nordmann P, Poirel L (April 2023). "NDM-9 resistance to taniborbactam". The Lancet. Infectious Diseases. 23 (4): 401–402. doi:10.1016/S1473-3099(23)00069-5. PMID 36796395.
  3. Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, et al. (February 2024). "Cefepime-Taniborbactam in Complicated Urinary Tract Infection". The New England Journal of Medicine. 390 (7): 611–622. doi:10.1056/NEJMoa2304748. PMID 38354140.
  4. "Cefepime/taniborbactam - VenatoRx Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: